Escitalopram in Patients With Generalized Anxiety Disorder

This study has been completed.
Sponsor:
Information provided by:
H. Lundbeck A/S
ClinicalTrials.gov Identifier:
NCT00902564
First received: May 14, 2009
Last updated: May 11, 2011
Last verified: May 2011
Results First Received: March 14, 2011  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Generalized Anxiety Disorder
Intervention: Drug: Escitalopram

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Escitalopram (5 to 20 mg Oral Tablets Daily) No text entered.

Participant Flow:   Overall Study
    Escitalopram (5 to 20 mg Oral Tablets Daily)  
STARTED     30  
COMPLETED     28  
NOT COMPLETED     2  
Withdrawal by Subject                 2  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Escitalopram (5 to 20 mg Oral Tablets Daily) No text entered.

Baseline Measures
    Escitalopram (5 to 20 mg Oral Tablets Daily)  
Number of Participants  
[units: participants]
  30  
Age  
[units: participants]
 
<=18 years     0  
Between 18 and 65 years     30  
>=65 years     0  
Age  
[units: years]
Mean ± Standard Deviation
  37.3  ± 12  
Gender  
[units: participants]
 
Female     19  
Male     11  
Hamilton Anxiety Scale (HAMA) [1]
[units: scores on a scale]
Mean ± Standard Deviation
  31.1  ± 5.3  
Clinical Global Impression Severity (CGI-S) [2]
[units: scores on a scale]
Mean ± Standard Deviation
  4.5  ± 0.6  
Sheehan Disability Scale (SDS) Work [3]
[units: scores on a scale]
Mean ± Standard Deviation
  6.8  ± 1.6  
Sheehan Disability Scale (SDS) Family [3]
[units: scores on a scale]
Mean ± Standard Deviation
  6.1  ± 2.0  
Sheehan Disability Scale (SDS) Social [3]
[units: scores on a scale]
Mean ± Standard Deviation
  6.8  ± 2.5  
[1] The HAMA is a 14-item rating scale designed to assess global anxiety symptoms. Each symptom is rated from 0 (absent) to 4 (severe). The total score of the 14 items ranges from 0 to 56.
[2] The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).
[3] The SDS comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scale, on which 0 = normal functioning and 10 = severe functional impairment.



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Effect of Escitalopram After 8 Weeks of Treatment in Patients With GAD Using the Hamilton Anxiety Scale (HAMA)   [ Time Frame: baseline and 8 weeks ]

2.  Secondary:   Effect of Escitalopram After 8 Weeks Using the Clinical Global Impression (CGI-I)   [ Time Frame: baseline and 8 weeks ]

3.  Secondary:   Effect of Escitalopram After 8 Weeks Using the Clinical Global Impression (CGI-S)   [ Time Frame: baseline and 8 weeks ]

4.  Secondary:   Percentage of Patients Who Responded to Escitalopram After 8 Weeks of Treatment Using CGI-I <= 2   [ Time Frame: baseline and 8 weeks ]

5.  Secondary:   Percentage of Patients Who Achieved Remission After 8 Weeks of Treatment Using CGI-S <= 2   [ Time Frame: baseline and 8 weeks ]

6.  Secondary:   Effect of Escitalopram After 8 Weeks Using Sheehan Disability Scale (SDS) Work   [ Time Frame: baseline and 8 weeks ]

7.  Secondary:   Effect of Escitalopram After 8 Weeks Using Sheehan Disability Scale (SDS) Family   [ Time Frame: baseline and 8 weeks ]

8.  Secondary:   Effect of Escitalopram After 8 Weeks Using Sheehan Disability Scale (SDS) Social   [ Time Frame: baseline and 8 weeks ]

9.  Secondary:   Percentage of Patients Who Responded According to >= 50% Improvement From Baseline to Week 8 in HAMA Total Score   [ Time Frame: baseline and 8 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Study Director
Organization: H. Lundbeck A/S
phone: Email contact via ext Lundbeck
e-mail: LundbeckClinicalTrials@lundbeck.com


No publications provided


Responsible Party: H. Lundbeck A/S
ClinicalTrials.gov Identifier: NCT00902564     History of Changes
Other Study ID Numbers: 12132A
Study First Received: May 14, 2009
Results First Received: March 14, 2011
Last Updated: May 11, 2011
Health Authority: Russia: Ministry of Health of the Russian Federation